Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

brown & burk uk ltd - etoricoxib - oral tablet - 30mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - nefopam hydrochloride - oral tablet - 30mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - mirtazapine - oral tablet - 30mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

medreich plc - nefopam hydrochloride - oral tablet - 30mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - mirtazapine - oral tablet - 30mg

Ισραήλ - Αγγλικά - Ministry of Health

tzamal bio-pharma ltd - pioglitazone as hydrochloride - tablets - pioglitazone as hydrochloride 15 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance .

Ισραήλ - Αγγλικά - Ministry of Health

tzamal bio-pharma ltd - pioglitazone as hydrochloride - tablets - pioglitazone as hydrochloride 45 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.as triple oral therapy in combination with- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance .

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - pioglitazone hydrochloride, quantity: 49.59 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: hyprolose; carmellose calcium; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea; in combination with insulin. as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - pioglitazone hydrochloride, quantity: 16.53 mg (equivalent: pioglitazone, qty 15 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; carmellose calcium - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea; in combination with insulin. as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - codeine phosphate hemihydrate 30mg;  ;  ;  ;   - tablet - 30 mg - active: codeine phosphate hemihydrate 30mg         excipient: acacia lactose monohydrate magnesium stearate maize starch purified talc - codeine phosphate is indicated for: the relief of mild to moderate pain (including pain associated with terminal illness, post-operative pain and headache), the relief of symptoms of diarrhoea (except diarrhoea caused by poisoning),